Forbes

Trump has publicly slammed pharma and health insurers for their alleged profiteering off the backs of patients. But his administration’s policies have had little impact.

A public health expert explains what you need to know about rising flu cases and how you and your loved ones can stay protected.

Study finds that psychotherapy during pregnancy can improve depression outcomes and could benefit infant brain and emotional development.

More December games could expose players and fans to dangerous cold, while an earlier season start could increase heat risks. Here's what's at stake.

Could conversations with ChatGPT affect your body? Researchers are exploring whether AI-related stress or reassurance might influence blood pressure, sleep and heart rate.

Gene therapy cut severe infections 93% in Wiskott-Aldrich syndrome, using patients’ own modified stem cells to treat a rare inherited immune disorder.

A simple but effective way to reduce firearm-related deaths is by promoting safe storage of guns in the home and other practical, evidence-based strategies.

CEO Dave Ricks built Eli Lilly into the first $1 trillion pharma company with its blockbuster weight-loss and diabetes drugs. But with more than 60% of revenue coming from them, the drug giant faces the risks of its own success.

Your immune cells are constantly aging. Cellino is launching a new service, called Reservoir, to let people securely store them from a simple blood draw for $5,000.

Research and consumer demand are validating the need for health and comfort designed into the home, but there are still challenges to bring it all toget

With the rise in premiums and deductibles not included in the CPI increase, it’s evident that certain healthcare costs are enhancing the affordability crisis.

A neurosurgeon explains what the 3.6% Social Security COLA for 2027 means for Medicare patients and its potential impact during the open enrollment period.

Whole-genome testing uncovered hidden cancer predisposition in children with leukemia, changing treatment and surveillance in a nationwide Swedish study.

In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.

“The Last Ditch Bar controversy reveals a deeper story: what it actually costs to live immunocompromised in a world that’s moved on from masks.”